medigraphic.com
ISSN 0210-5187 (Electronic)

2015, Number 2

<< Back Next >>

Med Cutan Iber Lat Am 2015; 43 (2)

Platelet-rich plasma: a review and management in non-healing cutaneous ulcers

Gómez SME, Azaña DJM, Escario TE, Gómez BGJ, López VMT, Martínez MML, Faura BC, Ezsol Z

Language: Spanish
References: 35
Page: 125-131
PDF size: 505.82 Kb.


ABSTRACT

In the last years there have been significant advances in wound therapy, as well as on the concept of chronic cutaneous ulcer as an inflammatory process in which proinflammatory citokines and a low level of growth factors are involved. According to this etiopathogenic hypothesis, new therapies have been developed, specially the use of autologous growth factors obtained from platelet rich plasma (PRP). This therapy has been increasingly used in different clinical and surgery applications like wound healing and regeneration of lost tissues. In this paper a review of the current employment status of PRP in non-healing cutaneous ulcers will be presented.


REFERENCES

  1. Lin P, Phillips T. Úlceras. En: Bolognia JL, Jorizzo JL, Rapan RP editors. Dermatología. Madrid: Elsevier; 2004, pp. 1631-1649.

  2. Velasco M. Aspectos diagnósticos y terapéuticos de las úlceras de las piernas. Actas Dermosifiliogr. 2011; 102: 780-790.

  3. Alsina-Gibert M, Pedregosa-Fauste S. Aplicación de membrana amniótica en el tratamiento de las úlceras crónicas de extremidades inferiores. Actas Dermosifiliogr. 2012; 103: 608-613.

  4. Burón AI, Fernández-Tresguerres A, Calvo M, Alfageme F et al. Tratamiento de úlceras cutáneas crónicas con plasma autólogo rico en plaquetas. Piel. 2012; 27: 429-434.

  5. Montón EJ, Pérez RS, Gómez BGJ. Experiencia clínica en el empleo de factores de crecimiento autólogos obtenidos de plasma rico en plaquetas. Cir Plast Iberolatinoam. 2007; 33: 155-162.

  6. Cohen S, Levi-Montalcini R. A nerve growth-stimulating factor isolated from snake venom. Proc Nat Acad Sci USA. 1956; 42: 571-574.

  7. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962; 237: 1555-1562.

  8. Raines EW, Ross R. Platelet-derived growth factor. I. High yield purification and evidence for multiple forms. J Biol Chem. 1982; 257 (9): 5154-5160.

  9. Seifert RA, Coats SA, Raines EW, Ross R, Bowen-Pope DF. Platelet-derived growth factor (PDGF) receptor alpha-subunit mutant and reconstituted cell lines demonstrate that transforming growth factor-beta can be mitogenic through PDGF A-chain-dependent and -independent pathways. J Biol Chem. 1994; 269: 13951-13955.

  10. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999; 14: 529-535.

  11. Sánchez M, Albillos J, Angulo F, Santisteban JM, Andia I. Platelet-rich plasma in muscle and tendon healing. Operative Techniques in Orthopaedics. 2012; 22: 16-24.

  12. De La Mata J. Platelet rich plasma. A new treatment tool for the rheumatologist? Reumatol Clin. 2012; [Epub ahead of print].

  13. Gehring S, Hoerauf H, Laqua H, Kirchner H, Klüter H. Preparation of autologous platelets for the ophthalmologic treatment of macular holes. Transfusion. 1999; 39: 144-148.

  14. Alio JL, Arnalich-Montiel F, Rodríguez AE. The role of “eye platelet rich plasma” (E-PRP) for wound healing in ophthalmology. Curr Pharm Biotechnol. 2012; 13: 1257-1265.

  15. Prakash S, Thakur A. Platelet concentrates: past, present and future. J Maxillofac Oral Surg. 2011; 10: 45-49.

  16. Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg. 2001; 107: 229-237.

  17. Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg. 2006; 118: 147e-159e.

  18. Quintero E, Sabater MM, Chimenos E, López J. Hemostasia y tratamiento odontológico. Av Odontoestomatol. 2004; 20: 247-261.

  19. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004; 91: 4-15.

  20. Sommeling CE et al. The use of platelet-rich plasma in plastic surgery: a systematic review. J Plast Reconstr Aesthet Surg. 2013; 66: 301-311.

  21. Hom DB, Linzie BM, Huang TC. The healing effects of autologous platelet gel on acute human skin wounds. Arch Facial Plast Surg. 2007; 9: 174-183.

  22. Rodríguez FJ, Palomar GMA, Torres García-Denche J. Plasma rico en plaquetas: fundamentos biológicos y aplicaciones en cirugía maxilofacial y estética facial. Rev Esp Cir Oral Maxilofac. 2012; 34: 8-17.

  23. Findikcioglu F, Findikcioglu K, Yavuzer R, Lortlar N, Atabay K. Effect of preoperative subcutaneous platelet-rich plasma and fibrin glue application on skin flap survival. Aesthetic Plast Surg. 2012; 36: 1246-1253.

  24. Franco D, Schettino AM, Spani F. Protocol for obtaining platelet-rich plasma (PRP), platelet-poor plasma (PPP), and thrombin for autologous use. Aesth Plast Surg. 2012; 36: 1254-1259.

  25. Anitua E, Prado R, Sánchez M, Orive G. Platelet-rich plasma: preparation and formulation operative. Techniques in Orthopaedics. 2012; 22: 25-32.

  26. Steven P, Arnoczky DVM, Delos D, Rodeo SA. What is platelet-rich plasma? Oper Tech Sports Med. 2011; 19: 142-148.

  27. Beca T, Hernández G, Morante S, Bascones A. Plasma rico en plaquetas. Una revisión bibliográfica. Av Periodon Implantol. 2007; 1: 39-52.

  28. Knighton DR, Fiegal VD, Doucette M et al. The use of topically applied platelet growth factors in chronic nonhealing wounds: a review. Wounds. 1989; 1: 71.

  29. Mazzucco L, Medici D, Serra M et al. The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. Transfusion. 2004; 44: 1013-1018.

  30. Conde ME et al. Plasma rico en plaquetas: aplicaciones en Dermatología. Actas Dermosifiologr. En prensa 2014.

  31. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics. 2008; 2: 1-12.

  32. International therapeutics: raloxifene, becaplermin and clopidrogel. [editorial] Farm Hosp. 1998; 22: 216-219.

  33. U.S. Food and Drug Administration. Regranex (becaplermin) Gel 0.01% October 2008. Consultado: (24/04/2013) Disponible en: http://google2.fda.gov/search?q=regranex&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=-archive%3AYes&output=xml_no_dtd&getfields=*

  34. Honorato J. Biotechnologic drugs and chemotherapy for infectious diseases. Rev Esp Quimioter. 2007; 20: 310-316.

  35. Boletín oficial del Estado (BOE) Real Decreto 1088/2005 del 16 de Septiembre. Requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión. Consultado:(07/05/2014) Disponible en: shttp://www.boe.es/buscar/act.php?id=BOE-A-2005-15514.




2020     |     www.medigraphic.com